Qaseem, AmirYost, JenniferEtxeandia-Ikobaltzeta, ItziarAbraham, George MJokela, Janet A.Forciea, Mary AnnMiller, Matthew C.Humphrey, Linda L.2022-08-232022-08-232021-02-092021-02-21<p>Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-8101. Epub ahead of print. PMID: 33560862. <a href="https://doi.org/10.7326/M20-8101">Link to article on publisher's site</a></p>0003-4819 (Linking)10.7326/M20-810133560862https://hdl.handle.net/20.500.14038/27381Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?en-USremdesivirhospitalized patientscoronavirus disease 2019COVID-19effectivenessharmsHealth Services AdministrationHealth Services ResearchInfectious DiseaseInternal MedicinePatient SafetyTherapeuticsVirus DiseasesJournal Articlehttps://escholarship.umassmed.edu/covid19/17821761505covid19/178